Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05729477 · ClinicalTrials.gov registry record · NA
A Prospective Multicenter Study To Assess The Clinical Outcomes Of Current Phacoemulsification Approach To Cataract Extraction Versus The Micor System Device
A NA study, sponsored by Carl Zeiss Meditec.
- Terminated
- Registry status
- NA
- Development phase
- 402
- Enrollment target
NCT05729477: Clinical Trial NA study, sponsored by Carl Zeiss Meditec.
NCT05729477 is a NA study that was terminated before completion, run by Carl Zeiss Meditec. The registered enrollment target is 402 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05729477, a NA study, was terminated before completion, sponsored by Carl Zeiss Meditec.
- TERMINATED
- Registry status
- NA
- Development phase
- 402 participants
- Enrollment target
Study Summary
The purpose of this research study is to evaluate the clinical outcomes of current phacoemulsification approaches to cataract extraction involving high-frequency thermogenic energy versus the use of the MICOR System device using low-energy segment removal with a micro-interventional irrigation/aspiration port to evacuate the lens in subjects undergoing routine cataract surgery.
Primary Outcome
1-Day postoperative UCVA measurement using LogMAR visual acuity charts
Interventions
- DEVICE miCOR System
- DEVICE Phaco Subject Cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2022-12-06 |
| Est. Completion | 2025-12-30 |
| Phase | NA |
Why NCT05729477 stopped before completion
NCT05729477 is an interventional study that assigns participants to a tested intervention. The registered 402 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which miCOR System is the first listed.
NCT05729477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05729477 about?
NCT05729477 is a clinical study titled "A Prospective Multicenter Study To Assess The Clinical Outcomes Of Current Phacoemulsification Approach To Cataract Extraction Versus The Micor System Device". The purpose of this research study is to evaluate the clinical outcomes of current phacoemulsification approaches to cataract extraction involving high-frequency thermogenic energy versus the use of the MICOR System device using low-energy segment removal with a micro-interventional irrigation/aspir...
What is the current status of trial NCT05729477?
This trial is currently terminated. It is a NA study. The enrollment target is 402 participants. The study started on 2022-12-06. Estimated completion is 2025-12-30.
What interventions are being tested in trial NCT05729477?
The interventions under investigation include: miCOR System (DEVICE), Phaco Subject Cohort (DEVICE).
Who is sponsoring clinical trial NCT05729477?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05729477's enrollment target sits among peer trials
402 245th of 2000 higher than 1,755 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04464226 · 402 participants · Phase 3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
- NCT05183763 · 402 participants · NA
Medication Adherence Program
- NCT06748222 · 402 participants · Phase 3
E-Mindfulness Approaches for Living After Breast Cancer
- NCT06896474 · 402 participants · NA
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI